GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Levofloxacin

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Select the usual regimen before the renal row

The 750, 500 and 250 mg renal paths differ. The 250 mg row has a specific uncomplicated-UTI exception and lacks dialysis adjustment information.

Before applying: Retain indication, usual dose, loading dose and maintenance interval together.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - LEVAQUIN

Product / population
Selected LEVAQUIN adult oral-tablet renal table; not pediatric or automatically an IV administration instruction.
Renal measure
Source-specific renal measure; see text

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Before using this finding

Do not select 750, 500 or 250 mg solely from clearance; begin with the indication-specific usual regimen.

No new official-label card was obtained for this product in v6.1. Earlier source layers, if present, were retained but not rechecked.

Renal guidance and important limits

Select the indication-specific usual regimen before using the adult renal table.

Usual regimenCrCl 20-49 mL/minCrCl 10-19 mL/min or HD/CAPD
750 mg every 24 hours750 mg every 48 hours750 mg once, then 500 mg every 48 hours
500 mg every 24 hours500 mg once, then 250 mg every 24 hours500 mg once, then 250 mg every 48 hours

For the 250 mg/day regimen, no adjustment at 20-49; at 10-19 use 250 mg every 48 hours except uncomplicated UTI, for which the source says no adjustment. No HD/CAPD adjustment information is supplied for that 250 mg row. At CrCl at least 50, the renal table requires no adjustment. Fluoroquinolone boxed warnings and indication restrictions remain separate selection requirements.

Source revision: Revision not established in selected retrieval | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/levaquin-drug/

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - LEVAQUIN

Authored v6.1; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - LEVAQUIN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Do not select 750, 500 or 250 mg solely from clearance; begin with the indication-specific usual regimen.

Dialysis evidence: A regimen is reported in selected content

Selected LEVAQUIN adult oral-tablet renal table; not pediatric or automatically an IV administration instruction.

Renal method: Source-specific renal measure; see text
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Professional guidance

UCSF - levofloxacin

Adult systemic levofloxacin; treatment regimens. Heme/BMT prophylaxis is a separate source regimen.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Sunnybrook - levofloxacin 750-mg renal strategy

Adult systemic levofloxacin; Canadian institutional guidance.

Renal method: CrCl in mL/min; source-specific replacement-therapy schedules.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Select the usual regimen before the renal row

The 750, 500 and 250 mg renal paths differ. The 250 mg row has a specific uncomplicated-UTI exception and lacks dialysis adjustment information.

How to use this: Retain indication, usual dose, loading dose and maintenance interval together.

GlobalRPh RX List - LEVAQUIN

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - LEVAQUINUCSF - levofloxacinSunnybrook - levofloxacin 750-mg renal strategy
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Historical indication, duration and organism material is retained. This import does not establish that these are preferred current treatment choices.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/levofloxacin/

Usual Dosing (Adults)

For CrCl at least 50 mL/min, usual doses are 250 or 500 mg every 24 hours infused over 60 minutes, or 750 mg every 24 hours infused over 90 minutes. Intravenous-to-oral conversion is at the physician's discretion.

Indication-specific every-24-hour regimens in the source:

  • Nosocomial pneumonia: 750 mg for 7-14 days.
  • Community-acquired pneumonia: 500 mg for 7-14 days or 750 mg for 5 days.
  • Acute bacterial sinusitis: 750 mg for 5 days or 500 mg for 10-14 days.
  • Acute bacterial exacerbation of chronic bronchitis: 500 mg for 7 days.
  • Complicated skin/skin-structure infection: 750 mg for 7-14 days; uncomplicated infection: 500 mg for 7-10 days.
  • Chronic bacterial prostatitis: 500 mg for 28 days.
  • Complicated urinary-tract infection or acute pyelonephritis: 750 mg for 5 days or 250 mg for 10 days.
  • Uncomplicated urinary-tract infection: 250 mg for 3 days.
  • Inhalational anthrax post-exposure, adults and children at least 6 months old weighing over 50 kg: 500 mg every 24 hours for 60 days. The source refers to another pediatric table for smaller children without reproducing its dose.
GRPH-levofloxacin-01 · Source section: Usual Dosing (Adults)Renal section finder

Organism and duration comments

For the 500 mg community-acquired pneumonia regimen the source lists methicillin-susceptible S. aureus, S. pneumoniae including multidrug-resistant strains, H. influenzae, H. parainfluenzae, K. pneumoniae, M. catarrhalis, C. pneumoniae, L. pneumophila and M. pneumoniae. The 750 mg pneumonia regimen lists S. pneumoniae excluding multidrug-resistant strains, H. influenzae, H. parainfluenzae, M. pneumoniae and C. pneumoniae.

The 750 mg complicated-UTI regimen lists E. coli, K. pneumoniae and P. mirabilis; the corresponding pyelonephritis indication includes E. coli with concurrent bacteremia. The 250 mg complicated-UTI regimen lists E. faecalis, a source entry written as 'Enterococcus cloacae', E. coli, K. pneumoniae, P. mirabilis and P. aeruginosa; the corresponding pyelonephritis indication lists E. coli. The unusual organism wording is preserved rather than silently corrected.

Anthrax prophylaxis should start promptly after suspected or confirmed aerosolized B. anthracis exposure. The source describes surrogate plasma concentrations as supporting likely benefit. Safety beyond 28 days in adults or 14 days in children was not studied in the cited context. Pediatric musculoskeletal adverse reactions occurred more often than with comparators; prolonged adult treatment requires a benefit-risk assessment.

GRPH-levofloxacin-02 · Source section: Organism and duration commentsRenal section finder

Renal Dosing

Adjust below CrCl 50 mL/min. The usual daily regimen determines the adjusted regimen:

  • Usual 750 mg daily: CrCl 20-49, 750 mg every 48 hours; CrCl 10-19 or HD/CAPD, 750 mg initially then 500 mg every 48 hours.
  • Usual 500 mg daily: CrCl 20-49, 500 mg initially then 250 mg every 24 hours; CrCl 10-19 or HD/CAPD, 500 mg initially then 250 mg every 48 hours.
  • Usual 250 mg daily: CrCl 20-49, no adjustment; CrCl 10-19, 250 mg every 48 hours, except no adjustment for uncomplicated UTI. The source provides no HD/CAPD information for this regimen.
GRPH-levofloxacin-03 · Source section: Renal DosingRenal section finder

Hemodialysis

Use the HD regimens above. The GlobalRPh comment states to give after dialysis on dialysis days.

GRPH-levofloxacin-04 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - LEVAQUIN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Selected LEVAQUIN adult oral-tablet renal table; not pediatric or automatically an IV administration instruction.

Renal method: Source-specific renal measure; see text
Source date: Revision not established in selected retrieval
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Do not select 750, 500 or 250 mg solely from clearance; begin with the indication-specific usual regimen.

Dialysis evidence: A regimen is reported in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Select the indication-specific usual regimen before using the adult renal table.

Usual regimenCrCl 20-49 mL/minCrCl 10-19 mL/min or HD/CAPD
750 mg every 24 hours750 mg every 48 hours750 mg once, then 500 mg every 48 hours
500 mg every 24 hours500 mg once, then 250 mg every 24 hours500 mg once, then 250 mg every 48 hours

For the 250 mg/day regimen, no adjustment at 20-49; at 10-19 use 250 mg every 48 hours except uncomplicated UTI, for which the source says no adjustment. No HD/CAPD adjustment information is supplied for that 250 mg row. At CrCl at least 50, the renal table requires no adjustment. Fluoroquinolone boxed warnings and indication restrictions remain separate selection requirements.

RDM61-rxlist-levofloxacin-387b432d8b-C1 · Source locator: Dosage and Administration: renal impairment; named precautions

Source-specific limits

No new official-label card was obtained for this product in v6.1. Earlier source layers, if present, were retained but not rechecked.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/levaquin-drug/
Retrieved
2026-09-10
Renal-function method
Source-specific renal measure; see text
Source date/version
Revision not established in selected retrieval
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
0adfaa127703d984661666a7305e7911a30d8221d47961025069022f54a77fc4
Separate professional-source layer

University and professional protocols

Professional

UCSF - levofloxacin

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adult systemic levofloxacin; treatment regimens. Heme/BMT prophylaxis is a separate source regimen.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Exactly 50 is unassigned in this source. Separate oral doses from multivalent cations by at least 2 hours.

UTI treatment - IV/oral
CrCl, mL/minSource-specific dose / instruction
>50500 mg every 24 hours
20-49500 mg once, then 250 mg every 24 hours
<20500 mg once, then 250 mg every 48 hours
Other infections - IV/oral
CrCl, mL/minSource-specific dose / instruction
>50750 mg every 24 hours
20-49750 mg every 48 hours
<20750 mg once, then 500 mg every 48 hours
Dialysis guidance - separate source-specific schedules
Levofloxacin dialysis
Dialysis setting / indicationSource-specific schedule
IHD standard500 mg once, then 250 mg every 48 hours
IHD pneumonia/Gram-negative bacteremia/Pseudomonas750 mg once, then 500 mg every 48 hours
CVVHD standard750 mg once, then 250 mg every 24 hours
CVVHD pneumonia/bacteremia/Pseudomonas750 mg once, then 500 mg IV every 24 hours
Read the retained text before reformatting

For CrCl >50 / 20-49 / <20 mL/min, UTI treatment uses 500 mg IV/orally daily / 500 mg once then 250 mg daily / 500 mg once then 250 mg every 48 hours. Other infections use 750 mg daily / 750 mg every 48 hours / 750 mg once then 500 mg every 48 hours.

IHD standard: 500 mg once then 250 mg every 48 hours. IHD pneumonia, Gram-negative bacteremia or Pseudomonas: 750 mg once then 500 mg every 48 hours.

CVVHD standard: 750 mg once then 250 mg daily; pneumonia/bacteremia/Pseudomonas: 750 mg once then 500 mg IV daily. Oral doses require separation from multivalent cations by at least 2 hours.

The exact CrCl 50 boundary is not allocated by the displayed >50 / 20-49 columns.

RDM30-015-levofloxacin-1 · Source locator: UCSF - levofloxacin; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/levofloxacin
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
3e51fc2d5816170a3bb4627678ac65c54c96024947dcc4e3d092090f7a749da5
Professional

Sunnybrook - levofloxacin 750-mg renal strategy

Open original reference

Open / share this exact local source

Sunnybrook Health Sciences Centre, Canada · Adult systemic levofloxacin; Canadian institutional guidance.

Renal method: CrCl in mL/min; source-specific replacement-therapy schedules.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Usual schedule: 750 mg daily. CrCl 30-49 mL/min: 750 mg loading, then 500 mg daily; 10-29: 750 mg every 48 hours. Below 10, PD or HD: 750 mg loading, then 500 mg every 48 hours, regardless of HD timing. CRRT retains usual dosing. This institutional approach differs from the UCSF 750-mg renal schedule and must not be blended with it.

RDM30-065-levofloxacin-1 · Source locator: Sunnybrook - levofloxacin 750-mg renal strategy; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://sunnybrook.ca/antimicrobial-stewardship/renal-dosing-and-insufficiency-drug-dosing-considerations/
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min; source-specific replacement-therapy schedules.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
81d8764a69c43f9cd8224438d8be5d1faf0c3a958561dae56cc07b1a7af82757

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/levofloxacin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
033e0352cdd6831fab014dc3c6387cdb692666b015585157402a83c50d583676
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report